Healthcare >> CEO Interviews >> September 3, 2004


MATTHEW EMMENS joined Shire Pharmaceuticals Group plc as Chief Executive and member of the Board in March 2003. Mr. Emmens began his career in international pharmaceuticals in 1974 when he joined Merck & Co. He held a wide range of sales, marketing and training positions with Merck & Co before moving in 1993 to help establish Astra Merck, the joint venture with Astra Pharmaceuticals. He later became its President and Chief Executive. Astra Merck Inc. became an independent, top 20 US pharmaceutical company with annualized sales in excess of $4 billion and 4000 employees. In 1999 he joined Merck KGaA and established EMD Pharmaceuticals, the company's US prescription pharmaceutical business. He was most recently based in Darmstadt, Germany as President of Merck's global prescription pharmaceuticals business, which in the year 2002 achieved sales of US $2 billion. A graduate of Fairleigh Dickenson University in Rutherford, New Jersey, US, Mr. Emmens earned a Bachelor of Science degree in Business Administration. Profile
TWST: As an entry point, what is Shire Pharmaceuticals?

Mr. Emmens: In short, Shire is a specialty pharmaceutical company

currently focused on serving the specialist physician and their